{"contentid": 488547, "importid": NaN, "name": "Merck & Co\u00e2\u0080\u0099s Organon spinoff billed as good news for all", "introduction": "US pharma giant Merck & Co has detailed plans for the Organon spinoff.", "content": "<p>US pharma giant Merck &amp; Co (NYSE: MRK) has detailed plans for the Organon spinoff.</p>\n<p>Management have said that the new standalone company is positioned to deliver low to mid-single digit revenue growth off its base in June 2021, when Organon will begin trading.</p>\n<p>The company will take Merck&rsquo;s women's health, biosimilars and established brands divisions with it in the split.</p>\n<h2>More than 60 medicines in Organon portfolio</h2>\n<p>Rob Davis, who will take over from Ken Frazier as Merck&rsquo;s chief executive the following month, said: &ldquo;The spinoff of Organon will help Merck become a leaner, more focused and agile company with stronger growth, and will enable significant operating efficiencies.</p>\n<p>&ldquo;Organon, as a standalone company, will be better positioned to realize its potential and to have a meaningful impact, particularly in women&rsquo;s health.</p>\n<p>&ldquo;We believe this transaction will create value for the patients both companies serve and for Merck shareholders.&rdquo;</p>\n<p>At launch, Organon&rsquo;s portfolio will consist of more than 60 medicines and products across the three core franchises.</p>\n<h2>'Only company of our size focused on women's health'</h2>\n<p>Kevin Ali, Organon&rsquo;s chief executive, said: &ldquo;Our day one portfolio consists of many well-known products that were once core to Merck&rsquo;s business but have since strategically received limited resources and investment.</p>\n<p>&ldquo;These are important medicines that we believe will be responsive to commercial investment, and with renewed management focus, we expect the portfolio to generate low to mid-single organic revenue growth off of a 2021 base.</p>\n<p>&ldquo;Additionally, as the only company of our size to be focused on women&rsquo;s health, we have a significant opportunity to do more to support women and their health, and the time is right to bring forward more options for patients and healthcare providers.&rdquo;</p>", "date": "2021-05-05 15:12:00", "meta_title": NaN, "meta_keywords": "Organon, Merck, spinoff, company, health, portfolio, billed, good, news, Co\u00e2\u0080\u0099s, pharma, giant, detailed, plans, Mercks, medicines, growth, women, focused", "meta_description": "US pharma giant Merck & Co has detailed plans for the Organon spinoff.", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 3, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-05-05 15:08:21", "updated": "2021-05-05 17:16:39", "access": NaN, "url": "https://www.thepharmaletter.com/article/merck-co-s-organon-spinoff-billed-as-good-news-for-all", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "merck_large.jpg", "image2id": "merck_small.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Pharmaceutical", "therapy area_tag": "Women's health", "topic_tag": "Companies, mergers and acquisitions, Management", "geography_tag": "USA", "company_tag": "Merck & Co, Organon", "drug_tag": NaN, "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-05-05 15:12:00"}